Lake Champlain Sea Grant

Abstract Lake Champlain is consistently ranked as one of the top fisheries for black bass Micropterus spp. in the United States. Tournament fishing on the lake has become increasingly popular, with dozens of tournaments held annually since the early 2000s and at least 60 more planned for 2017. The largest of these tournaments launch from Plattsburgh, New York, and their frequency has generated concerns among fishery managers and the public over post-weigh-in mortality and stockpiling. However, relatively little is known about the disposition of tournament-caught black bass in large (>750 km2) lake systems. To address this information gap, we T-bar-tagged 1,141 Largemouth Bass M. salmoides and 1,160 Smallmouth Bass M. dolomieu collected from tournament anglers launching from Plattsburgh during 2011 and 2012. Additionally, 38 Largemouth Bass and 53 Smallmouth Bass caught during professional bass tournaments were implanted with radio tags prior to release. Angler-reported T-bar recaptures yielded a 9.8% recovery rate, with over half of the tag recoveries occurring within the first month postrelease, primarily within 5 km of their release. Radio-tagged fish were tracked for up to 383 d following release into Cumberland Bay, 1 km northeast of Plattsburgh. Overall, 43% of radio-tagged Largemouth Bass and 56% of radio-tagged Smallmouth Bass left the bay, although there was variation in dispersal patterns between years. One T-bar-tagged fish and no radio-tagged fish returned to their proximate capture locations. Despite the absence of fish returning to their original capture location, results from both T-bar tagging and radiotelemetry suggest that long-term (>1 month) stockpiling in Cumberland Bay is not an issue. However, short-term (<1 month) stockpiling, coupled with an abundance of publicly accessible fishing areas in Plattsburgh, may warrant concern for increased black bass mortality during the weeks after release. Received April 24, 2016; accepted February 8, 2017 Published online April 4, 2017

Ovarian cancer is the leading cause of death for all gynecologic malignancies in developed countries, largely owing to the late stage of diagnosis. Despite response to initial surgery and chemotherapy, more than 65% of patients will have recurrent or persistent diseases. Approximately 50% of patients with recurrent ovarian cancer are asymptomatic. Recurrences are often diagnosed using a combination of tests, including cancer antigen 125, computed tomography, magnetic resonance imaging and positron emission tomography scan. The most significant prognostic factor among women with recurrent ovarian cancer is the length of time from initial diagnosis to recurrence. Treatment of recurrent ovarian cancer involves chemotherapy, with or without surgery. In selected patients, secondary cytoreductive surgery might significantly improve survival. Radiotherapy may have a role in the treatment of a small group of patients with localized symptomatic masses. New treatment modalities for women with recurrent ovarian cancer are needed, as none of the available treatments are curative.